Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21289239 | 0.82 | IDO1 (0.53) | RXFP1LMNATP53MAPTTHRB | |
| SCHEMBL22812952 | 0.82 | PDGFRB (0.75) | LMNAMAPTPDGFRBIDO1AKT1 | |
| SCHEMBL19000116 | 0.79 | ADRB2 (0.57) | PDGFRBAKT1ALDH1A1 | |
| SCHEMBL28818753 | 0.78 | ADRB2 (0.56) | PDGFRBAKT1ALDH1A1 | |
| SCHEMBL22262655 | 0.77 | PDGFRB (0.52) | MALT1PDGFRBIDO1FAAH | |
| SCHEMBL21289874 | 0.75 | IDO1 (0.54) | RXFP1LMNATP53MAPTTHRB | |
| SCHEMBL14145469 | 0.75 | LMNA (0.53) | RXFP1LMNATP53MAPTMALT1 | |
| SCHEMBL9342656 | 0.74 | KMT2A (0.72) | LMNAMAPTFAAHMGLL | |
| SCHEMBL14599424 | 0.74 | ACHE (0.59) | PDGFRBIDO1 | |
| SCHEMBL20918176 | 0.73 | IDO1 (0.56) | PDGFRBIDO1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | IDO1, IDO2, TPH1 | RXFP1 209/4885LMNA 3506/4885TP53 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.